Axsome Therapeutics, Inc. (AXSM)

155.22 +1.03 (+0.67%) USD  |  NASDAQ  |  Dec 24, 10:36
More

Axsome Therapeutics SG&A Expense (TTM): 514.57M for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for AXSM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Gilead Sciences, Inc. 5.886B
ACADIA Pharmaceuticals, Inc. 523.36M
Fortress Biotech, Inc. 108.70M
TG Therapeutics, Inc. 208.25M
Karyopharm Therapeutics, Inc. 109.63M